Skip to main content

Table 3 Characteristics of neuroprotectant use

From: Current management of intracerebral haemorrhage in China: a national, multi-centre, hospital register study

Neuroprotectant

n (%*)

Edaravone

95 (8.4)

Ganglioside GM1

29 (2.6)

Cattle encephalon glycoside and ignotin

112 (9.9)

Cinepazide

56 (5.0)

Citicholine

334 (29.6)

Other†

198 (17.5)

Unspecified

321 (28.4)

  1. *As a proportion of all patients on any neuroprotectant therapy (n = 1130); groups are not mutually exclusive as 1 patient may be on more than 1 neuroprotectant
  2. †Use of agents including deproteinised calf blood extracts, adenosine triphosphate, cerebroprotein extracts, cytidine disodium triphosphate, lysine, piracetam, meclofenoxate, and sodium fructose diphosphate.